Accelerates recovery from Acute MS relapses*[2,19] 
- In multiple head-to-head clinical studies, there were no demonstrated differences between the efficacy and safety of IV steroids and ACTH*[20-22] 
- Mechanism of action may extend beyond steroidogenic effects through binding in the melanocortin system†‡ 
- Well-established side effect profile
- Flexible delivery via self-administered injection
Acthar insurance coverage is generally very favorable (~90%) when prescribed for those select patients who: 
- Express tolerability concerns with IV steroids
- Report an inadequate response to IV steroids
- Have poor venous access
- Common adverse reactions for H.P. Acthar Gel are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain 
- *The exact chemical form of ACTH used in these studies is unknown.
†While the exact mechanism of action of Acthar is unknown, further investigation is being conducted.
‡This information is based on nonclinical data and the relationship to clinical benefit is unknown.
Indication for Use
H.P. Acthar® Gel (repository corticotropin injection), or Acthar, is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.